 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

---
- Amgen's Lumakras treats a specific non-small-cell lung cancer form that scientists
  had struggled with, calling it 'undruggable.'Amgen's Lumakras treats a specific
  non-small-cell lung cancer form that scientists had struggled with, calling it 'undruggable.'Shares
  of Amgen (AMGN) - Get Reportgot a ...


Amgen Rises After Key Lung-Cancer Treatment Cleared by FDA

---
- Prime Therapeutics will begin to move its 2,200 Minnesota employees back into its
  Eagan offices starting in August, it said Wednesday. Prime has told its employees
  that, provided cases of Covid-19 remain low in Minnesota, it will raise its capacity
  at the 385,000-square-foot Eagan office building, known internally as Prime Landing,
  up to about 25% starting August 2.


Prime Therapeutics announces August return-to-work date

---
- Five Prime Therapeutics (NASDAQ:FPRX) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are
  both small-cap medical companies, but which is the superior investment? We will
  contrast the two companies based on the strength of their dividends, institutional
  ownership, valuation, risk, earnings, analyst ...


Financial Survey: Five Prime Therapeutics (NASDAQ:FPRX) versus Sonoma Pharmaceuticals (NASDAQ:SNOA)

---
- Shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) have earned a consensus rating
  of Hold from the nine research firms that are presently covering the firm, MarketBeat.com
  reports. Seven investment analysts have rated the stock with a hold rating and two
  have assigned a buy rating ...


Brokerages Set Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Target Price at $30.75

---
- Five Prime Therapeutics, Inc. (NASDAQ:FPRX) saw a large growth in short interest
  during the month of March. As of March 31st, there was short interest totalling
  2,970,000 shares, a growth of 56.3% from the March 15th total of 1,900,000 shares.
  Based on an average daily volume of 2,090,000 shares, ...


Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Short Interest Up 56.3% in March

---
- Amgen (AMGN) announces that it has completed its previously announced tender offer
  to purchase all outstanding shares of Five Prime Therapeutics (FPRX) in a deal valued...


Amgen completes $1.9B acquisition of Five Prime Therapeutics

---
- Amgen Successfully Completes Acquisition Of Five Prime Therapeutics Amgen Successfully
  Completes Acquisition Of Five Prime Therapeutics PR Newswire THOUSAND OAKS, Calif.,
  April 16, 2021 THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN)
  today announced that it has...


Amgen Successfully Completes Acquisition Of Five Prime Therapeutics

---
- Wall Street analysts predict that Five Prime Therapeutics, Inc. (NASDAQ:FPRX) will
  report $6.90 million in sales for the current fiscal quarter, according to Zacks
  Investment Research. Two analysts have made estimates for Five Prime Therapeutics
  earnings, with estimates ranging from $5.00 ...


Brokerages Expect Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Will Announce Quarterly Sales of $6.90 Million

---
- This indicator may be signaling that FPRX's price has further to drop, since it
  moved below its price 14 days ago. Traders may consider selling the stock, shorting
  the stock, or exploring put options...


Five Prime Therapeutics (FPRX, $37.65) enters Downtrend as Momentum indicator drops below 0 level on Apr 05, 2021

---
- Alyeska Investment Group L.P. acquired a new stake in shares of Five Prime Therapeutics,
  Inc. (NASDAQ:FPRX) in the 4th quarter, according to its most recent disclosure with
  the Securities and Exchange Commission. The institutional investor acquired 209,691
  shares of the biotechnology companys...


Alyeska Investment Group L.P. Acquires Shares of 209,691 Five Prime Therapeutics, Inc. (NASDAQ:FPRX)

FivePrime is dis­cov­er­ing and devel­op­ing novel ther­a­peu­tic pro­teins and anti­bod­ies by sys­tem­at­i­cally screen­ing all rel­e­vant pro­teins in the human body to find the best pro­tein for treat­ment of a given clin­i­cal indi­ca­tion. FivePrime’s Pro­Screen Engine enables the rapid pro­duc­tion and screen­ing of all ther­a­peu­ti­cally rel­e­vant pro­teins in medically-​​focused assays at the high­est qual­ity stan­dards in the indus­try. This pow­er­ful approach is the polar oppo­site of the industry’s tra­di­tional “one pro­tein at a time”. The Pro­Screen Engine com­prises the defin­i­tive pro­tein col­lec­tion and screen­ing process for bio­log­ics dis­cov­ery and is unprece­dented in its effi­ciency, qual­ity, and scale. In addi­tion to DBL Investors, investors include Domain Asso­ciates, Ver­sant Ven­tures, Kleiner Perkins Cau­field and Byers, Texas Pacific Group, Health­Cap, and Advanced Tech­nol­ogy Ventures.

Watchers	3,132
52-Wk Low	$2.64
52-Wk High	$38.90

Market Cap	$1.77B
Volume (M)	1.01M
52-Wk High	$38.90
52-Wk Low	$2.64

FPRX Five Prime Therapeutics, Inc.

About

Feed

News

Fundamentals